Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yin Cheong Wong, Shuai Qian & Zhong Zuo. (2012) Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions. Expert Opinion on Drug Metabolism & Toxicology 8:7, pages 833-854.
Read now
Read now
Shu-Feng Zhou, Bo Wang, Li-Ping Yang & Jun-Ping Liu. (2010) Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metabolism Reviews 42:2, pages 268-354.
Read now
Read now
Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:2, pages 89-295.
Read now
Read now
B. L. Blake, R. L. Rose, R. B. Mailman, P. E. Levi & E. Hodgson. (1995) Metabolism of thioridazine by microsomal monooxygenases: relative roles of P450 and flavin-containing monooxygenase. Xenobiotica 25:4, pages 377-393.
Read now
Read now
Articles from other publishers (17)
Andrea Greiter-Wilke, Sonia Roberts, Katja Heinig, David Waiz, Roland Jenni & Henry Holzgrefe. (2022) Nonclinical cardiovascular safety assessment of thioridazine: Impact of autonomic tone, body temperature, and choice of species. Journal of Pharmacological and Toxicological Methods 115, pages 107167.
Crossref
Crossref
Tyler B. Hughes & S. Joshua Swamidass. (2017) Deep Learning to Predict the Formation of Quinone Species in Drug Metabolism. Chemical Research in Toxicology 30:2, pages 642-656.
Crossref
Crossref
Katsunori Sasahara, Akira Mashima, Tatsusada Yoshida & Hiroshi Chuman. (2015) Molecular dynamics and density functional studies on the metabolic selectivity of antipsychotic thioridazine by cytochrome P450 2D6: Connection with crystallographic and metabolic results. Bioorganic & Medicinal Chemistry 23:17, pages 5459-5465.
Crossref
Crossref
So Hee Im, Myoung Joo Park, Hyewon Seo, Sung Heum Choi, Sang Kyum Kim & Sung-Hoon Ahn. (2014) Determination of mesoridazine by liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic study in rats. Journal of Chromatography B 958, pages 117-123.
Crossref
Crossref
Michael Murray. (2006) Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. Journal of Pharmacy and Pharmacology 58:7, pages 871-885.
Crossref
Crossref
Donald J. AbrahamJeffrey M. Brown, Jie Jack Li & Michael W. Sinz. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
161
218
.
Bo Wen & Mingyan Zhou. (2009) Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. Chemico-Biological Interactions 181:2, pages 220-226.
Crossref
Crossref
Pedro DoradoEva M Peñas-LLedóAlfredo de la Rubia & Adrián LLerena. (2009)
Relevance of
CYP2D6
-1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients
. Pharmacogenomics 10:7, pages 1083-1089.
Crossref
Crossref
R H K Thanacoody, A K Daly, J G Reilly, I N Ferrier & S H L Thomas. (2007) Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy. Clinical Pharmacology & Therapeutics 82:5, pages 555-565.
Crossref
Crossref
Sungwoon Choi, Deborah Haggart, Lawrence Toll & Gregory D. Cuny. (2004) Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorganic & Medicinal Chemistry Letters 14:17, pages 4379-4382.
Crossref
Crossref
Roland Berecz, Alfredo de la Rubia, Pedro Dorado, Pedro Fernández-Salguero, Marja-Liisa Dahl & Adrián LLerena. (2003) Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. European Journal of Clinical Pharmacology 59:1, pages 45-50.
Crossref
Crossref
Donald J. AbrahamC. Anthony Altar, Arnold R. Martin & Andrew Thurkauf. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
599
672
.
Adrián LLerena, Roland Berecz, Alfredo de la Rubia, Pedro Fernández-Salguero & Pedro Dorado. (2001) Effect of Thioridazine Dosage on the Debrisoquine Hydroxylation Phenotype in Psychiatric Patients With Different CYP2D6 Genotypes. Therapeutic Drug Monitoring 23:6, pages 616-620.
Crossref
Crossref
Adrián Llerena, Roland Berecz, Alfredo de la Rubia, Maria-Jesús Norberto & Julio Benítez. (2000) Use of the Mesoridazine/Thioridazine Ratio as a Marker for CYP2D6 Enzyme Activity. Therapeutic Drug Monitoring 22:4, pages 397-401.
Crossref
Crossref
Juan A. Carrillo, Sara I. Ramos, Angustias G. Herraiz, Adrian Llerena, Jose A. G. Agundez, Roland Berecz, Marisol Duran & Julio Benítez. (1999) Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients. Journal of Clinical Psychopharmacology 19:6, pages 494-499.
Crossref
Crossref
Ge Lin, Ka-Wing Chu, Lyaquatali A. Damani & Edward M. Hawes. (1996) Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs. Journal of Pharmaceutical and Biomedical Analysis 14:6, pages 727-738.
Crossref
Crossref
Chin B. Eap, Theo W. Guentert, Martina Schäublin-Loidl, Max Stabl, Liliane Koeb, Kerry Powell & Pierre Baumann. (1996) Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*. Clinical Pharmacology & Therapeutics 59:3, pages 322-331.
Crossref
Crossref